Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)
HS Rugo(Texas Oncology), SM Tolaney(Memorial Sloan Kettering Cancer Center), W. J. John(Memorial Sloan Kettering Cancer Center), MN Dickler(Memorial Sloan Kettering Cancer Center), Yi Lu(Shandong Provincial Hospital), Peter Kabos(University of Colorado Anschutz Medical Campus), Suzanne R.L. Young(Eli Lilly (United States)), Ian C. P. Smith(Royal Marsden Hospital)
Cited by 16
Related Papers
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Data-analysis strategies for image-based cell profiling
|Nature Methods|2017|789
Chemical Approaches to Addressing the Instability and Toxicity of Lead–Halide Perovskite Absorbers
|Inorganic Chemistry|2016|336